Role of Inorganic and Organic Fractions in Animal Manure Compost in Lead Immobilization and Microbial Activity in Soil by Masahiko Katoh, Wataru Kitahara, Takeshi Sato

Get full text

A Case of Drastic Reduction of Membranous Substances in the Pharynx by Interprofessional Cooperative Oral Care by Masahiko Okubo, Hideyuki Kamimura, Tsuyoshi Sato, Shoichiro Kokabu

Get full text

Neurotrophic Keratopathy after Trigeminal Nerve Block for Treatment of Postherpetic Neuralgia by Aya Kodama-Takahashi, Koji Sugioka, Tomoko Sato, Koichi Nishida, Keiichi Aomatsu, Masahiko Fukuda, Yoshikazu Shimomura

Get full text

Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study by Itsukaichi A, Yoshikawa F, Fuchigami A, Iwata Y, Sato G, Miyagi M, Hirose T, Uchino H

“…Atsushi Itsukaichi,* Fukumi Yoshikawa,* Ayako Fuchigami, Yoko Iwata, Genki Sato, Masahiko Miyagi, Takahisa Hirose, Hiroshi Uchino Department of Diabetes, Metabolism and Endocrinology, Toho University Graduate School of Medicine, Tokyo, Japan*These authors contributed equally to this workCorrespondence: Hiroshi Uchino, Department of Diabetes, Metabolism, and Endocrinology, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan, Tel +81-3-3762-4151, Fax +81-3-3765-6488, Email h.uchino@med.toho-u.ac.jpPurpose: Imeglimin is a novel oral antidiabetic agent that improves glucose tolerance. …”
Get full text